Ribavirin in chronic hepatitis C: past and future

References

• Manns MP, McHutchison JG, Gordon SC et al. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet358, 958–965 (2001).
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med.347, 975–982 (2002).
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Sette H Jr, Morgan TR et al. Peginterferon-α and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med.140, 346–355 (2004).
   PubMed Web of Science ®Google Scholar
• Heathcote J, Zeuzem S. Pegylated interferon monotherapy for chronic hepatitis C. Semin. Liver Dis.24(Suppl. 2), 39–45 (2004).
   PubMed Web of Science ®Google Scholar
• Bronowicki JP, Ouzan D, Asselah T et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon α-2a plus ribavirin Gastroenterology131, 1040–1048 (2006).
   PubMed Web of Science ®Google Scholar
• Dusheiko GM, Hezode C, Pol S. Treatment of chronic hepatitis C with telaprevir in combination with peginterferon α 2A with or without ribavirin: further interim analysis. Results of the Prove 2 study. J. Hepatol.48(Suppl. 2), S26 (2008).
   Web of Science ®Google Scholar
• Jen J, Laughlin M, Chung C et al. Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic–pharmacodynamic models. Clin. Pharmacol. Ther.72, 349–361 (2002).
   PubMed Web of Science ®Google Scholar
• Larrat S, Stanke-Labesque F, Plages A, Zarski JP, Bessard G, Souvignet C. Ribavirin quantification in combination treatment of chronic hepatitis C. Antimicrob. Agents Chemother.47, 124–129 (2003).
   PubMed Web of Science ®Google Scholar
• Loustaud-Ratti V, Alain S, Rousseau A et al. Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology47, 1453–1461 (2008).
   PubMed Web of Science ®Google Scholar
• Maynard M, Pradat P, Gagnieu MC, Souvignet C, Trepo C. Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients. Antivir. Ther.13(4), 607–611 (2008).
   PubMed Web of Science ®Google Scholar
• Fernandez H, Banks G, Smith R. Ribavirin: a clinical overview. Eur. J. Epidemiol.2, 1–14 (1986).
   PubMedGoogle Scholar
• Murata Y, Falsey AR. Respiratory syncytial virus infection in adults. Antivir. Ther.12, 659–670 (2007).
   PubMed Web of Science ®Google Scholar
• Snell NJ. Ribavirin current status of a broad spectrum antiviral agent. Expert Opin. Pharmacother.2, 1317–1324 (2001).
   PubMedGoogle Scholar
• Reichard O, Andersson J, Schvarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet337, 1058–1061 (1991).
   PubMed Web of Science ®Google Scholar
• Brillanti S, Garson J, Foli M et al. A pilot study of combination therapy with ribavirin plus interferon α for interferon α-resistant chronic hepatitis C. Gastroenterology107, 812–817 (1994).
   PubMed Web of Science ®Google Scholar
• Di Bisceglie AM, Conjeevaram HS, Fried MW et al. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med.123, 897–903 (1995).
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Manns M, Patel K et al. International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology123, 1061–1069 (2002).
   PubMed Web of Science ®Google Scholar
• Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology41(2), 275–279 (2005).
   PubMed Web of Science ®Google Scholar
• Dixit NM, Perelson AS. The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus. Cell Mol. Life Sci.63, 832–842 (2006).
   PubMed Web of Science ®Google Scholar
• Markland W, McQuaid TJ, Jain J, Kwong AD. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with a interferon. Antimicrob. Agents Chemother.44(4), 859–866 (2000).
   PubMed Web of Science ®Google Scholar
• Zhou S, Liu R, Baroudy BM, Malcolm BA, Reyes GR The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology310, 333–342 (2003).
   PubMed Web of Science ®Google Scholar
• Asahina Y, Izumi N, Enomoto N et al. Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J. Hepatol.43, 623–629 (2005).
   PubMed Web of Science ®Google Scholar
• Chevaliez S, Brillet R, Lazaro E, Hezode C, Pawlotsky JM. Analysis of ribavirin mutagenicity in human hepatitis C virus infection. J. Virol.81, 7732–7741 (2007).
   PubMed Web of Science ®Google Scholar
• Feld JJ, Nanda S, Huang Y et al. Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology46, 1548–1563 (2007).
   PubMed Web of Science ®Google Scholar
• Neumann AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science282, 103–107 (1998).
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM, Dahari H, Neumann AU et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology126, 703–714 (2004).
   PubMed Web of Science ®Google Scholar
• Bruchfeld A, Lindahl K, Schvarcz R, Ståhle L. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther. Drug Monit.24, 701–708 (2002).
   PubMed Web of Science ®Google Scholar
• Jen JF, Glue P, Gupta S, Zambas D, Hajian G. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther. Drug Monit.22, 555–565 (2000).
   PubMed Web of Science ®Google Scholar
• Glue P, Schenker S, Gupta S, Clement RP, Zambas D, Salfi M. The single dose pharmacokinetics of ribavirin in subjects with chronic liver disease. Br. J. Clin. Pharmacol.49, 417–421 (2000).
   PubMed Web of Science ®Google Scholar
• Wade JR, Snoeck E, Duff F, Lamb M, Jorga K. Pharmacokinetics of ribavirin in patients with hepatitis C virus. Br. J. Clin. Pharmacol.62, 710–714 (2006).
   PubMed Web of Science ®Google Scholar
• Glue P. The clinical pharmacology of ribavirin. Semin. Liver Dis.19, 17–24 (1999).
   PubMed Web of Science ®Google Scholar
• De Franceschi L, Fattovich G, Turrini F. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology31(4), 997–1004 (2000).
   PubMed Web of Science ®Google Scholar
• Gaeta GB, Precone DF, Felaco FM et al. Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in ‘real world’ patients with chronic hepatitis C. Aliment. Pharmacol. Ther.16, 1633–1639 (2002).
   PubMed Web of Science ®Google Scholar
• Dieterich DT, Wasserman R, Bräu N et al. Once-weekly epoetin α improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon α. Am. J. Gastroenterol.98, 2491–2499 (2003).
   PubMed Web of Science ®Google Scholar
• Afdhal NH, Dieterich DT, Pockros PJ et al.; Proactive Study Group. Epoetin α maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology126, 1302–1311 (2004).
   PubMed Web of Science ®Google Scholar
• Shiffman ML, Salvatore J, Hubbard S et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin α. Hepatology46, 371–379 (2007).
   PubMed Web of Science ®Google Scholar
• Crespo M, Pou L, Esteban JI et al. Early monitoring of ribavirin serum concentration is not useful to optimize hepatitis C virus treatment in HIV-coinfected patients. Antivir. Ther.12, 1217–1223 (2007).
   PubMed Web of Science ®Google Scholar
• Marcellin P, Jensen DM, Hadzyiannis SJ, Ferenci P. Differnciation of early virologic response (EVR) into RVR, complete EVR (cEVR) and partial EVR(pEVR), allows a more precise prediction of SVR in HCV genotype 1 patients treated with peginterferon α 2a and ribavirin. Hepatology46, 818A (2007) (Abstract).
   Web of Science ®Google Scholar
• Ferenci P, Fried MW, Shiffman ML et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon α-2a (40 KD)/ribavirin. J. Hepatol.43, 425–433 (2005).
   PubMed Web of Science ®Google Scholar
• Nicot F, Legrand-Abravanel F, Lafont T et al. Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV. J. Med. Virol.80, 1523–1529 (2008).
   PubMed Web of Science ®Google Scholar
• Christensen PB, Alsio AA, Buhl MR et al. Ribavirin concentration at W4 is an independent predictor for sustained virological response after treatment of hepatitis C genotype 2/3 (Nordynamic trial). J. Hepatol.48(Suppl. 2), S6–S7 (2008).
   Google Scholar
• Arase Y, Ikeda K, Tsubota A et al. Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C. Intervirology48, 138–144 (2005).
   PubMed Web of Science ®Google Scholar
• Donnerer J, Grahovac M, Stelzl E et al. Ribavirin levels and haemoglobin decline in early virological responders and non-responders to hepatitis C virus combination therapy. Pharmacology76, 136–140 (2006).
   PubMed Web of Science ®Google Scholar
• Rendón AL, Núñez M, Romero M et al. Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients. J. Acquir. Immune Defic. Syndr.39, 401–405 (2005).
   PubMed Web of Science ®Google Scholar
• Bosch ME, Sánchez AJ, Rojas FS, Ojeda CB. Ribavirin: analytical determinations since the origin until today. J. Pharm. Biomed. Anal.45, 185–193 (2007).
   PubMed Web of Science ®Google Scholar
• Dahari H, Markatou M, Zeremski M et al. Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. J. Hepatol.47, 23–30 (2007).
   PubMed Web of Science ®Google Scholar